Sanofi-Aventis — Medicare Part D spending
Rank #9 by attributed Part D spend · 30 tracked drugs · CMS data year 2023
About $7,885,034,020 of Medicare Part D spending in 2023 is attributed to Sanofi-Aventis across the 30 of its drugs tracked here, ranking it #9 among manufacturers on this site. Its biggest Part D drug is Lantus Solostar at $3,157,233,282. Attribution uses the CMS manufacturer lists and is indicative, not definitive. These are aggregate program figures, not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Sanofi-Aventis drugs in Medicare Part D (2023)
| Brand | Generic | Total spend | Per dosage unit | Beneficiaries | Spend rank |
|---|---|---|---|---|---|
| <a href="/drug/lantus-solostar-insulin-glargine-hum-rec-anlog/">Lantus Solostar</a> | Insulin Glargine,Hum.Rec.Anlog | $3,157,233,282 | $30.28 | 1,198,294 | #12 |
| <a href="/drug/dupixent-pen-dupilumab/">Dupixent Pen</a> | Dupilumab | $1,081,417,351 | $951.72 | 41,263 | #46 |
| <a href="/drug/lantus-insulin-glargine-hum-rec-anlog/">Lantus</a> | Insulin Glargine,Hum.Rec.Anlog | $735,735,411 | $29.55 | 279,981 | #72 |
| <a href="/drug/dupixent-syringe-dupilumab/">Dupixent Syringe</a> | Dupilumab | $633,292,043 | $966.09 | 20,849 | #84 |
| <a href="/drug/toujeo-solostar-insulin-glargine-hum-rec-anlog/">Toujeo Solostar</a> | Insulin Glargine,Hum.Rec.Anlog | $541,871,908 | $94.16 | 163,635 | #99 |
| <a href="/drug/toujeo-max-solostar-insulin-glargine-hum-rec-anlog/">Toujeo Max Solostar</a> | Insulin Glargine,Hum.Rec.Anlog | $488,777,502 | $94.06 | 106,268 | #106 |
| <a href="/drug/multaq-dronedarone-hcl/">Multaq</a> | Dronedarone HCl | $409,348,468 | $13.08 | 71,895 | #132 |
| <a href="/drug/aubagio-teriflunomide/">Aubagio</a> | Teriflunomide | $353,934,133 | $320.81 | 6,565 | #154 |
| <a href="/drug/soliqua-100-33-insulin-glargine-lixisenatide/">Soliqua 100-33</a> | Insulin Glargine/Lixisenatide | $302,998,642 | $59.80 | 59,571 | #163 |
| Kevzara | Sarilumab | $110,312,728 | $1,882.05 | 4,167 | #372 |
| Ambien | Zolpidem Tartrate | $12,138,036 | $21.93 | 2,421 | #1158 |
| Apidra Solostar | Insulin Glulisine | $8,643,475 | $37.10 | 2,418 | #1291 |
| Plavix | Clopidogrel Bisulfate | $7,228,749 | $8.02 | 3,289 | #1365 |
| Jevtana | Cabazitaxel | $6,064,538 | $9,358.85 | 87 | #1425 |
| Ambien Cr | Zolpidem Tartrate | $5,862,427 | $21.71 | 1,089 | #1443 |
| Xenpozyme | Olipudase Alfa-Rpcp | $5,083,777 | $7,410.75 | — | #1488 |
| Admelog Solostar | Insulin Lispro | $4,074,927 | $13.40 | 11,113 | #1571 |
| Sarclisa | Isatuximab-Irfc | $3,679,042 | $159.16 | 56 | #1616 |
| Mozobil | Plerixafor | $3,484,575 | $8,772.85 | 111 | #1634 |
| Avapro | Irbesartan | $3,264,701 | $8.55 | 1,228 | #1662 |
| Apidra | Insulin Glulisine | $2,769,322 | $28.62 | 676 | #1731 |
| Flomax | Tamsulosin HCl | $2,408,758 | $9.54 | 891 | #1776 |
| Admelog | Insulin Lispro | $1,393,724 | $10.76 | 4,971 | #1967 |
| Avalide | Irbesartan/Hydrochlorothiazide | $1,080,180 | $9.59 | 361 | #2068 |
| Arava | Leflunomide | $1,045,335 | $49.67 | 88 | #2082 |
| Lovenox | Enoxaparin Sodium | $675,990 | $26.06 | 390 | #2245 |
| Elitek | Rasburicase | $571,449 | $1,968.84 | 58 | #2310 |
| Priftin | Rifapentine | $420,148 | $4.86 | 1,302 | #2415 |
| Amaryl | Glimepiride | $197,208 | $3.19 | 315 | #2632 |
| Primaquine | Primaquine Phosphate | $26,191 | $1.60 | 300 | #3122 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Frequently asked questions
How much Medicare Part D spending does Sanofi-Aventis get?
In 2023, about $7,885,034,020 of Medicare Part D spending is attributed to Sanofi-Aventis across the 30 of its drugs tracked here. Its biggest is Lantus Solostar at $3,157,233,282. This is gross program spending, not what patients pay. Source: CMS, data year 2023.
What is Sanofi-Aventis's top Medicare Part D drug?
Among the drugs tracked here, Sanofi-Aventis's highest Part D spending in 2023 is Lantus Solostar at $3,157,233,282 (national rank #12 by total spend).
Is manufacturer attribution exact?
No. CMS may list multiple manufacturers per drug, and labeler relationships change over time. We attribute each drug to its primary listed manufacturer, so these rollups are indicative rather than definitive. Always check the underlying CMS file for a specific drug.
Keep exploring
Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not prices. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-21